Methods and compositions for the treatment of influenza

Patent metadata

Field	Value
Publication number	US-9511125-B2
Application number	US-201013502989-A
Country	US
Kind code	B2
Filing date	Oct 21, 2010
Priority date	Oct 21, 2009
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

A method to treat Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes, is disclosed. The method includes the use of an individual's fecal chymotrypsin level as an indicator e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated.

First claim

What is claimed is:

1. A method for treating Influenza in a mammal or a bird, comprising orally administering to the mammal or bird suffering from said influenza a therapeutically effective amount of a pharmaceutical composition containing a sole bioactive substance that consists of digestive enzymes wherein the digestive enzymes comprise at least one protease and at least one lipase, wherein the protease and lipase in the pharmaceutical composition in U.S.P. units are present in a ratio of protease to lipase of from about 1:1 to about 20:1, and wherein influenza is treated by said composition.

2. The method of claim 1 , wherein the Influenza is Influenza Type A or Subtype H1N1.

3. The method of claim 1 , wherein the digestive enzymes further comprise at least one amylase, cellulase, sucrase or maltase.

4. The method of claim 1 , wherein the digestive enzymes are pancreatin.

5. The method of claim 1 , wherein the at least one protease comprises chymotrypsin and trypsin.

6. The method of claim 1 , wherein the digestive enzymes are, independently, derived from an animal source, a microbial source, a fungal source, or are synthetically prepared.

7. The method of claim 6 , where the animal source is a pig pancreas.

8. The method of claim 1 , wherein the mammal is a pig, horse, cow, dog, cat, monkey, rat, mouse, sheep, goat or human.

9. The method of claim 1 , wherein the digestive enzymes further comprise at least one amylase.

10. The method of claim 9 , wherein the pharmaceutical composition comprises: amylase from about 10,000 to about 60,000 in U.S.P., units protease from about 10,000 to about 70,000 in U.S.P., units lipase from about 4,000 to about 30,000 U.S.P., chymotrypsin from about 2 to about 5 mg, and trypsin from about 60 to about 100 mg.

11. The method of claim 9 , wherein the at least one amylase of the pharmaceutical composition is present in the pharmaceutical composition in an amount of from about 10,000 to about 60,000 U.S.P. units per dose.

12. The method of claim 1 , further comprising vaccinating the mammal or bird with a trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV), treating the mammal or bird with an anti-viral medication, or both.

13. The method of claim 1 , wherein the protease and lipase in the pharmaceutical composition in U.S.P. units are present in a ratio of protease to lipase of from about 4: 1 to about 10: 1.

14. The method of claim 1 , wherein the pharmaceutical composition is a dosage formulation selected from the group consisting of: a pill, a tablet, a capsule, a microcapsule, a mini-capsule, a time released capsule, a mini-tab, a sprinkle, and a combination thereof.

15. The method of claim 1 , wherein the at least one protease of the pharmaceutical composition is present in the pharmaceutical composition in an amount of from about 10,000 to about 70,000 U.S.P. units per dose.

16. The method of claim 1 , wherein the at least one lipase of the pharmaceutical composition is present in the pharmaceutical composition in an amount of from about 4,000 to about 30,000 U.S.P. units per dose.

17. The method of claim 1 , wherein the protease activity of the composition is not less than about 156 U.S.P. units/mg.

18. The method of claim 1 , wherein the protease activity of the composition is not less than about 175 U.S.P. units/mg.

19. The method of claim 1 , wherein the protease activity of the composition is not less than about 195 U.S.P. units/mg.

20. The method of claim 1 , wherein the protease and lipase in the pharmaceutical composition in U.S.P. units are present in a ratio of protease to lipase of 4:1, 7:1, 10:1 or 12:1.

Assignees

• Fallon Joan M
• Heil Matthew F
• Fallon James J
• Szigethy James
• Curemark Llc

Inventors

• Fallon Joan M
• Heil Matthew F
• Fallon James J
• Szigethy James

Classifications

• A61K2039/5252

  inactivated (killed) · CPC title

• A61K39/145

  Orthomyxoviridae, e.g. influenza virus · CPC title

• A61K38/47

  acting on glycosyl compounds (3.2), e.g. cellulases, lactases · CPC title

• A61K38/465 Primary

  acting on ester bonds (3.1), e.g. lipases, ribonucleases · CPC title

• A61K38/54 Primary

  Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53 · CPC title